希罗达治疗肝癌后的肝癌超微结构的变化

开篇：润墨网以专业的文秘视角，为您筛选了一篇希罗达治疗肝癌后的肝癌超微结构的变化范文，如需获取更多写作素材，在线客服老师一对一协助。欢迎您的阅读与分享！

摘 要 目的:了解希罗达治疗后的肝癌超微结构的变化。方法:通过术前服用希罗达与未服用希罗达肝癌手术切除标本的对比,了解肝癌经希罗达治疗后超微结构的变化。结果:希罗达治疗肝癌后肝癌超微结构的变化表现为细胞接触松弛,胞质空虚,线粒体肿胀或空泡化;粗面型内质网减少;核浆比例减少,常染色质减少;异染色质增多,可见核浓缩、碎裂或溶解,核仁缩小或消失,并可见凋亡小体。结论:希罗达治疗后肝癌超微结构的变化说明希罗达能诱导肝癌细胞发生凋亡并抑制其生长。

关键词 希罗达 肝癌 超微结构

doi:10.3969/j.issn.1007-614x.2010.23.184

AbstractObjective:Learn the influence Xeloda treatment to liver ultrastructural changes of liver cancer.Methods:By giving or not giving capecitabine preoperatively to patients who were ill with liver cancer,ultrastructure variation of liver cancer cell that was induced by capecitabine could be learned from the difference.Results:ultrastructure variation of live cancer cell induced by capecitabine were such follows:cell-cell junctions were loose,the cytoplasm was hollow,the mitochondria vacuolalized or swelled,Rouf-surfaced endoplasmic reticulum and eu-chromatin reduced,the ratio between nucleus and cytoplasm reduced too;heterochromatin increased.The nucleus condensed、segregated and dissolved;the nucleolus reduced or disappeared,and the apoptotic bodies could be found.Conclusion:The ultrastructure change of liver cancer treated by capecitabine showed that capecitabine could induce apoptosis and inhibit growth of liver cancer cell.

KeywordsCapecitabine;Liver cancer;Ultrastructure variation

希罗达是一种口服的5-氟尿嘧啶(5-FU)的前体药物,口服后以完整的形式通过胃肠道[1]。希罗达已广泛应用于结直肠癌、乳腺癌等肿瘤的临床化疗,疗效已得到证实[2,3]。本文旨在探讨希罗达治疗后肝癌超微结构的变化,为其在肝癌中的临床应用提供依据。

资料与方法

2001年1月～2004年3月在我院行手术切除原发性肝癌病例40例,男30例,女10例;年龄32～68岁,中位年龄42.3岁。40例患者按住院顺序随机分为两组,每组各20例,一组术前服用希罗达2500mg/m2(分2次口服)7～14天,另一组术前未服用希罗达。肿瘤切除后,迅速切取部分肝癌组织切成1mm×1mm×1mm薄片,置于预冷的3%戊二醛液中固定;术后病检均报告为肝细胞癌。

方法:把置于预冷的3%戊二醛液中固定的肝癌标本制成超薄切片,在HITACHI-H600透视型电子显微镜下观察、照相;了解肝癌超微结构的变化。

结 果

术前未服用希罗达者的肝癌细胞超微结构的变化表现为细胞形态不规则,连接紧密,间歇不清;核浆比例大,线粒体、内质网丰富;细胞核核膜完整,常染色质多,异染色质少;核仁大或数目多;可见核仁边集、核畸变或核内假包涵体形成。服用希罗达者的肝癌细胞超微结构的变化表现为细胞接触松弛,胞质空虚,线粒体肿胀或空泡化;粗面型内质网减少;核浆比例减少,常染色质减少;异染色质增多,可见核浓缩、碎裂或溶解,核仁缩小或消失,并可见凋亡小体。